Company
Headquarters: Lianyungang, China
Employees: 28,903
CN¥418.67 Billion
CNY as of Jan. 1, 2026
US$59.68 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| AstraZeneca | $284.38 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥30.98 B |
| EBITDA | CN¥8.25 B |
| Gross Profit TTM | CN¥26.74 B |
| Profit Margin | 24.10% |
| Operating Margin | 21.49% |
| Quarterly Revenue Growth | 12.70% |
Jiangsu Hengrui Medicine Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600276 wb_incandescent